The KHLHX protein: A potential drug target and biomarker in theHLA region

Target Name: KLHL20

NCBI ID: G27252

KLHL20

The KHLHX protein: A potential drug target and biomarker in theHLA region

TheHLA region is one of the most promising drug targets in the immune system. The HLA-DRB1 gene is a key regulator of the immune response and has been implicated in a variety of autoimmune diseases, including HIV, cancer, and autoimmune disorders. The KHLHX gene, located on the HLA-DRB1 gene, has also been shown to play a role in the immune response and has been potential drug targets in the HLA region.

KHLHX is a 21-kDa protein that is expressed in various tissues and cells, including the immune system, tissues, and organs. It is a part of the HLA-DRB1 gene family and is responsible for the production of the KLHL1 and KLHL2 proteins. The KLHL1 protein is a key regulator of the immune response and has been shown to play a role in the regulation of immune cell function and inflammation. The KLHL2 protein is a negative regulator of the immune response and has been shown to play a role in the regulation of inflammation and autoimmune diseases.

Recent studies have suggested that KHLHX may be a potential drug target in the HLA region. The KLHL1 protein has been shown to play a role in the regulation of immune cell function and has been implicated in the development of autoimmune diseases. Additionally, the KLHL2 protein has been shown to play a role in the regulation of inflammation and has been implicated in the development of inflammatory diseases.

One of the potential advantages of targeting KHLHX is its expression in a variety of tissues and cells, including the immune system. This makes it a potential target for drugs that can modulate its expression or activity in these cells. Additionally, the KLHLX protein is a cytoplasmic protein, which means that it is primarily expressed in the cytoplasm of cells and is not targeted to the cell nucleus. This may make it a more attractive target for small molecules that can inhibit its activity without affecting the activity of other proteins.

Another potential advantage of targeting KHLHX is its role in the regulation of the immune response. The KLHL1 protein has been shown to play a role in the regulation of T cell development and function, as well as the regulation of cell death. The KLHL2 protein has been shown to play a role in the regulation of inflammation and immune cell function. These functions make KHLHX a potential target for drugs that can modulate its expression or activity in these cells.

In conclusion, the KHLHX protein is a potential drug target and biomarker in the HLA region. Its expression in various tissues and cells, including the immune system, makes it a potential target for drugs that can modulate its expression or activity. Additionally, its role in the regulation of the immune response and inflammation makes it a potential target for drugs that can modulate its expression or activity in these cells. Further research is needed to determine the full potential of KHLHX as a drug target and biomarker.

Protein Name: Kelch Like Family Member 20

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex involved in interferon response and anterograde Golgi to endosome transport. The BCR(KLHL20) E3 ubiquitin ligase complex mediates the ubiquitination of DAPK1, leading to its degradation by the proteasome, thereby acting as a negative regulator of apoptosis (PubMed:20389280). The BCR(KLHL20) E3 ubiquitin ligase complex also specifically mediates 'Lys-33'-linked ubiquitination (PubMed:24768539). Involved in anterograde Golgi to endosome transport by mediating 'Lys-33'-linked ubiquitination of CORO7, promoting interaction between CORO7 and EPS15, thereby facilitating actin polymerization and post-Golgi trafficking (PubMed:24768539). Also acts as a regulator of endothelial migration during angiogenesis by controlling the activation of Rho GTPases. The BCR(KLHL20) E3 ubiquitin ligase complex acts as a regulator of neurite outgrowth by mediating ubiquitination and degradation of PDZ-RhoGEF/ARHGEF11 (PubMed:21670212). In case of tumor, the BCR(KLHL20) E3 ubiquitin ligase complex is involved in tumor hypoxia: following hypoxia, the BCR(KLHL20)complex mediates ubiquitination and degradation of PML, potentiating HIF-1 signaling and cancer progression (PubMed:21840486)

The "KLHL20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets